​

Syndax Pharmaceuticals Ownership | Who Owns Syndax Pharmaceuticals?

OverviewForecastRevenueFinancialsChartTranscripts

Syndax Pharmaceuticals Ownership Summary

Syndax Pharmaceuticals is owned by 107.63% institutional investors, 1.32% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 10.57% of SNDX shares. Vanguard Health Care Inv is the top mutual fund, with 3.50% of its assets in Syndax Pharmaceuticals shares.

SNDX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockSyndax Pharmaceuticals107.63%1.32%-8.95%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de9.03M10.57%$119.43M
Kynam capital management, lp8.52M9.97%$112.63M
Blackrock7.91M9.28%$162.33M
Goldman sachs group5.95M6.97%$78.67M
Vanguard group4.88M5.71%$64.54M
Wellington management group llp4.23M4.96%$55.98M
State street3.62M4.25%$74.37M
Stempoint capital lp2.87M3.36%$37.98M
Soleus capital management2.49M2.92%$32.94M
Avoro capital advisors2.27M2.66%$30.08M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Stempoint capital lp2.87M9.48%$37.98M
Kynam capital management, lp8.52M6.66%$112.63M
Saturn v capital management988.53K5.12%$13.07M
Aisling capital management lp1.02M4.81%$13.55M
Lion point capital, lp55.00K3.81%$727.10K
Kingdon capital management2.00M3.77%$26.44M
Silverarc capital management1.23M3.56%$16.27M
Prosight management, lp551.54K3.38%$11.32M
Sphera funds management1.38M3.30%$18.26M
Exome asset management318.90K3.17%$4.22M

Top Buyers

HolderShares% AssetsChange
Goldman sachs group5.95M0.01%4.34M
Kynam capital management, lp8.52M6.66%2.68M
Assenagon asset management2.06M0.04%1.60M
Soleus capital management2.49M2.07%1.40M
Stempoint capital lp2.87M9.48%1.14M

Top Sellers

HolderShares% AssetsChange
Eversept partners, lp343.40K0.40%-3.76M
Orbimed advisors---1.93M
Bvf inc/il---1.88M
Avoro capital advisors2.27M0.43%-1.61M
State street3.62M0.00%-1.20M

New Positions

HolderShares% AssetsChangeValue
Octagon capital advisors lp904.00K1.97%904.00K$11.95M
Prosight management, lp551.54K3.38%551.54K$11.32M
Altium capital management lp370.00K1.39%370.00K$4.89M
Cubist systematic strategies358.07K0.03%358.07K$4.73M
Exome asset management318.90K3.17%318.90K$4.22M

Sold Out

HolderChange
Tfc financial management-1.00
Nelson, van denburg & campbell wealth management group-13.00
Srs capital advisors-14.00
Riggs asset managment-26.00
Innealta capital-48.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2024216-5.68%91,955,1243.35%1070.99%119-4.03%58-1.69%
Sep 30, 202422511.39%88,858,8691.79%1040.99%12110.00%59-3.28%
Jun 30, 20242002.56%87,296,966-3.26%1020.66%109-3.54%6011.11%
Mar 31, 20241954.28%90,236,9731.79%1240.77%113-4.24%5431.71%
Dec 31, 2023187-5.56%88,652,89124.90%1261.22%11822.92%41-31.67%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Health Care Inv2.99M3.50%-
Vanguard US Total Market Shares ETF2.60M3.01%4.69K
Vanguard Total Stock Mkt Idx Inv2.55M2.97%-
iShares Russell 2000 ETF2.15M2.50%-18.64K
SPDR® S&P Biotech ETF2.10M2.44%-22.52K
Vanguard Institutional Extnd Mkt Idx Tr1.29M1.50%2.04K
Eventide Healthcare & Life Sciences I1.18M1.37%391.07K
Franklin Biotechnology Discv A(acc)USD814.51K0.95%81.30K
Fidelity Small Cap Index809.22K0.94%-15.15K
iShares Russell 2000 Growth ETF724.33K0.84%-3.44K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 04, 2025Metzger Michael A Chief Executive OfficerSell$117.56K
Feb 10, 2025Goldan Keith A. Chief Financial OfficerSell$58.56K
Feb 10, 2025Metzger Michael A Chief Executive OfficerSell$206.02K
Feb 10, 2025Gallagher Neil President, Head of R&DSell$71.60K
Jun 14, 2024Goldan Keith A. Chief Financial OfficerBuy$25.04K

Insider Transactions Trends

DateBuySell
2025 Q1-4
2024 Q21-
2024 Q1--
2023 Q3-5
2023 Q2-5

SNDX Ownership FAQ

Who Owns Syndax Pharmaceuticals?

Syndax Pharmaceuticals shareholders are primarily institutional investors at 107.63%, followed by 1.32% insiders and -8.95% retail investors. The average institutional ownership in Syndax Pharmaceuticals's industry, Biotech Stocks , is 68.48%, which Syndax Pharmaceuticals exceeds.

Who owns the most shares of Syndax Pharmaceuticals?

Syndax Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (9.03M shares, 10.57%), Kynam capital management, lp (8.52M shares, 9.97%), and Blackrock (7.91M shares, 9.28%). Together, they hold 29.83% of Syndax Pharmaceuticals’s total shares outstanding.

Does Blackrock own Syndax Pharmaceuticals?

Yes, BlackRock owns 9.28% of Syndax Pharmaceuticals, totaling 7.91M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 162.33M$. In the last quarter, BlackRock increased its holdings by 354.33K shares, a 4.69% change.

Who is Syndax Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Stempoint capital lp is Syndax Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 9.48% of its assets in 2.87M Syndax Pharmaceuticals shares, valued at 37.98M$.

Who is the top mutual fund holder of Syndax Pharmaceuticals shares?

Vanguard Health Care Inv is the top mutual fund holder of Syndax Pharmaceuticals shares, with 3.50% of its total shares outstanding invested in 2.99M Syndax Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools